Previous Article | Next Article 
Molecular and Cellular Biology, December 1999, p. 8028-8032, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Immunological Development and Cardiovascular
Function Are Normal in Annexin VI Null Mutant Mice
Tim E.
Hawkins,1
Jürgen
Roes,2
Daryl
Rees,3
Jayne
Monkhouse,3 and
Stephen E.
Moss1,*
Department of Physiology, University College
London, London WC1E 6BT,1 Department of
Medicine, Windeyer Institute of Biomedical Sciences, University College
London, London W1P 6DB,2 and Wolfson
Institute for Biomedical Research and Centre for Clinical Pharmacology,
University College London, London WC1E 6JJ,3
United Kingdom
Received 18 August 1999/Accepted 25 August 1999
 |
ABSTRACT |
Annexins are calcium-binding proteins of unknown function but which
are implicated in important cellular processes, including anticoagulation, ion flux regulation, calcium homeostasis, and endocytosis. To gain insight into the function of annexin VI, we
performed targeted disruption of its gene in mice. Matings between
heterozygous mice produced offspring with a normal Mendelian pattern of
inheritance, indicating that the loss of annexin VI did not interfere
with viability in utero. Mice lacking annexin VI reached sexual
maturity at the same age as their normal littermates, and both males
and females were fertile. Because of interest in the role of annexin VI
in cardiovascular function, we examined heart rate and blood pressure
in knockout and wild-type mice and found these to be identical in the
two groups. Similarly, the cardiovascular responses of both sets of
mice to septic shock were indistinguishable. We also examined
components of the immune system and found no differences in thymic,
splenic, or bone marrow lymphocyte levels between knockout and
wild-type mice. This is the first study of annexin knockout mice, and
the lack of a clear phenotype has broad implications for current views
of annexin function.
 |
INTRODUCTION |
The annexins are a family of
calcium-binding proteins encoded by at least 12 different genes in
mammals and by numerous other genes in invertebrates and plants.
Annexins have been intensively studied because of their possible
involvement in a wide range of important biological processes,
including phospholipase A2 and protein kinase C inhibition,
apoptosis, blood coagulation, vesicle trafficking, cell transformation,
and calcium homeostasis (1, 7). All annexins bind to
negatively charged phospholipids in the presence of Ca2+
(such as those enriched in the inner leaflet of the plasma membrane), and the idea that soluble cytosolic annexins become associated with
intracellular membrane lipids in activated cells is a likely paradigm
for annexin function. Calcium binding by annexins is mediated by a
complex binding site that has more structural similarity to the
Ca2+-binding site in phospholipase A2 than to
other Ca2+-binding proteins, such as calmodulin
(10). Most annexins have four tandem repeats of the
conserved domain that defines the protein family, and it is the
-helical bundles created by these repeats that form the
Ca2+-binding sites.
Annexin VI is unique within the family in that it contains eight
conserved repeats. In the crystal structure, these are arranged as two
four-repeat lobes oriented perpendicularly to one another and separated
by a linker between repeats four and five (2). As with other
annexins, the function of annexin VI is far from clear, but there are
reports of its association with endocytic vesicles (11, 16),
and it has been linked with budding of clathrin-coated pits (12,
15). However, the observation that endocytosis occurs normally in
A431 cells that lack annexin VI supports the view that this process is
not an essential function of the protein (23). Annexin VI is
also strongly expressed in the heart, and studies with transgenic mice
showed that annexin VI overexpression targeted to cardiomyocytes led to
cardiomyopathy and heart failure (8). Analysis of
cardiomyocytes isolated from these mice revealed that basal
Ca2+ levels and the amplitude of Ca2+ spikes
were both reduced, with concomitant changes in contractile properties.
Loss of annexin VI has also been linked to cell transformation. Thus,
annexin VI was strongly down-regulated in melanocytes during their
progression from a normal to a highly metastatic malignant phenotype
(6). Consistent with this, stable expression of annexin VI
in A431 cells restrains both their growth in culture and their ability
to form tumors in vivo (24, 25).
 |
MATERIALS AND METHODS |
Preparation of an annexin VI targeting construct.
The mouse
annexin VI targeting construct was generated by a novel long-range
genomic fusion PCR technique with the Expand Long Template or the
Expand High Fidelity PCR kit (Boehringer Mannheim). The template was
genomic DNA prepared from the embryonic stem (ES) cells, of the 129 cell line, to be targeted. Two amplification products were generated,
one with primers MAVI-1 (5'-TTGGTTTCTGCTGCAGAACCTGAGACCAT-3') and MAVI-2 (5'-GATTTGCGGTTTAAACTCTGGGAAGTCGTGGACAGAGC-3'),
which yielded a 7.5-kb genomic fragment extending from exon 2 to
exon 3, and a second with primers MAVI-3
(5'-ACTTCCCAGAGTTTAAACGACGCAAATCAGGATGCTGAGG-3') and
MAVI-4 (5'-TTCCTGGCTCTGCTTGTTGCTGCGGGAGGT-3'), which yielded a 2.2-kb product extending from exon 3 to exon 4. Primers MAVI-2 and MAVI-3 have a central region of complementarity into which we
introduced a PmeI site. A 9.7-kb fusion PCR product was
generated with primers MAVI-1 and MAVI-4, with a mixture of the two
amplimers as a template. A 5.8-kb BamHI/BclI
fragment of the fusion product was then cloned into pBluescript SK.
Finally, a neomycin resistance cassette was cloned into the engineered
PmeI site in exon 3 of the cloned fusion product, and the
plasmid was linearized for transfection.
Generation of annexin VI null mutant mice.
The ES cell line
E14-1, of 129/ola origin (19), was cultured on feeder layers
of Neor STO cells (kindly provided by Mike Owen, Imperial
Cancer Research Fund, London, United Kingdom) and transfected with the
annexin VI targeting construct. Neomycin-resistant ES cell colonies
were screened by PCR for integration of the construct at the correct locus. ES cells containing one disrupted annexin VI allele were injected into 3.5-day-old blastocysts from C57BL/6 donors and returned
to pseudopregnant F1 hybrid foster females. Chimeric offspring were checked for germ line transmission of the mutation by
crossing them with C57BL/6 mice, and mice heterozygous for the mutation
in annexin VI were used to establish a breeding colony.
Analysis of cardiovascular function.
Measurements of heart
rate and mean arterial blood pressure (MAP) in the conscious mouse
under resting conditions and during and after toxic shock (caused by
intravenous administration of Escherichia coli
lipopolysaccharide [LPS] at 4 mg/kg of body weight) were performed as
described elsewhere (18).
Flow cytometry.
Analyses were performed as described
previously (19) with splenocytes, thymocytes, and bone
marrow cells. All antibodies were from PharMingen, and triple-staining
fluorescence-activated cell sorting (FACS) was done on a Becton
Dickinson FACSCalibur and analyzed with CellQuest software.
SDS-PAGE and Western blotting.
Tissue samples (~1
mm3) were homogenized on ice in 1 ml of lysis buffer (10 mM
Tris-HCl [pH 7.4], 50 mM NaCl, 10 mM EGTA, 1 mM dithiothreitol, 1%
Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride, and 1 mM each of
the small peptide inhibitors chymostatin, leupeptin, and pepstatin).
Particulate matter was pelleted by centrifugation, and supernatant
protein concentrations were determined with the Bio-Rad
detergent-compatible protein assay kit. Proteins were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on
10% polyacrylamide gels and transferred to Immobilon P (Millipore) for
Western blotting. Membranes were probed as described previously
(23) with antisera against annexins I (rabbit polyclonal), II (mouse monoclonal, kindly provided by V. Gerke, Muenster, Germany), V (rabbit polyclonal), and VI (rabbit polyclonal). Protein bands were
visualized by using chemiluminescence or Western blue (Promega).
 |
RESULTS |
As a first step towards generating annexin VI null mutant mice, we
used a novel PCR-based technique to prepare a targeting construct
(8a). The targeting construct contained the gene for neomycin resistance inserted into exon 3. Intron-exon boundaries are
highly conserved between human and mouse annexins, so although the
mouse annexin VI gene had not been characterized, predictions based on
the structure of the human annexin VI gene proved to be accurate
(21, 22). The wild-type and disrupted alleles were readily
distinguished by PCR with primers MAVI-4 and MAVI-5 (5'-ACCGAGGCTCTGTCCACGACTTCCC-3'), located in exons 4 and 3, respectively, on either side of the Neor gene (Fig.
1a). Note that although MAVI-4 was used
to amplify the original fragment of genomic DNA, it was excluded from
the targeting construct. This technique yielded a single product of 2.2 kb in control (+/+) mice, two products of 2.2 and 3.3 kb in heterozygous (+/
) mice, and a single 3.3-kb product in homozygous null (
/
) mutant mice (Fig. 1b). Mice that carried one copy of the
disrupted gene were interbred to generate pups that were +/+, +/
, and
/
for annexin VI as determined by genomic PCR of DNA extracted from
tail snips. Pups from 13 litters from heterozygous parents were
genotyped in this way, and the ratios of +/+, +/
, and
/
mice
(Fig. 1c) did not differ significantly from the predicted Mendelian
ratios of 1:2:1 for nonlethal alleles. Thus, under laboratory conditions annexin VI knockout pups were no less viable than their wild-type littermates.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Disruption of the mouse annexin VI gene locus.
Genotyping was done by genomic PCR of DNA extracted from tail snips.
Primers MAVI-4 (which lies beyond the end of the targeting construct)
and MAVI-5 were used as shown in panel a. Disrupted alleles of annexin
VI have a 1.1-kb insert in exon 3 which increases the size of this PCR
product from 2.2 to 3.3 kb. The results of PCRs with these primers and
template DNA from wild-type (+/+), heterozygous (+/ ), and homozygous
null ( / ) mice, as shown in panel b, were resolved on a 1% agarose
gel and visualized by ethidium bromide staining. The ratios of +/+,
+/ , and / pups from +/ × +/ matings are shown in panel c.
|
|
At a gross phenotypic level, loss of annexin VI had no discernible
impact. The morphology of muscle and the major organs, including the
heart, lung, brain, kidney, liver, thymus, spleen, testes, and ovaries,
was examined histologically, and no obvious changes were observed in
annexin VI
/
mice. This implies that annexin VI is not required
during the development of gross body structures in the mouse. The
knockout mice have also to date shown no loss of viability up to 1 year
of age compared to wild-type mice. Furthermore, +/+ × +/+, +/
× +/
, and
/
×
/
matings revealed no differences in fertility
with respect to average litter sizes, indicating that loss of annexin
VI also has no significant effect under these conditions on the ability
to mate or on the ability to carry, give birth to, or suckle young as
determined by pup viability (results not shown).
Given the absence of an overt phenotype under laboratory conditions, we
investigated the possibility that another member of the annexin gene
family might compensate for the loss of annexin VI. This might be
particularly true for annexin V, which according to cladistic analysis
is the closest relative of annexin VI in the gene family
(22). Since such functional compensation might be reflected
in altered gene expression, we examined the levels of expression of
annexins I, II, V, and VI by Western blotting of whole-tissue protein
extracts from splenocytes, heart, and liver of +/+ and
/
mice (Fig.
2). Although we surveyed only a sample of
the mammalian annexin gene family, those that we investigated are, like
annexin VI, the most widely expressed and therefore the most prone to
changes in expression linked to functional compensation. However, these
blots clearly revealed no major differences in expression between +/+
and
/
mice for any of these annexins, except for the disrupted
annexin VI.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of annexins (Anx) in annexin VI knockout
mice. Protein samples (40 µg of total protein per lane) from
splenocytes, whole heart tissue, and liver tissue were resolved by
SDS-PAGE and transferred to polyvinylidene difluoride membranes for
Western blotting. The annexin V blot was developed by
chemiluminescence, while the others were developed with Western blue
substrate.
|
|
We next examined components of the immune system, given that annexin VI
is strongly up-regulated during development of both B and T lymphocytes
(3). The immature and mature T-cell populations of the
thymus and spleen were classified by their surface expression of CD3,
CD4, and CD8. For each tissue, a typical wild-type FACS distribution
plot for CD4 and CD8 is shown (Fig. 3).
The numbers of cells in each population (determined from the quadrants
of the FACS plot), averaged for two wild-type and two knockout mice, are shown in each case in the corresponding bar chart. These results show that annexin VI
/
mice are not significantly different from
wild-type mice in terms of the proportions of CD4+ and
CD8+ T cells in the thymus or spleen. Furthermore, there
were no significant differences in the proportions of immature
(CD3
) and mature (CD3+) T cells in the thymus
(data not shown). Triple staining of surface antigens was also used to
characterize subpopulations of B cells. While all B cells express the
CD45/B220 antigen, surface expression of immunoglobulin M (IgM) and IgD
changes with maturation. The results for the IgM/B220 and the IgM/IgD
staining patterns, displayed as FACS plots and bar charts (as for Fig.
3), again show that the proportions of developing B-cell precursors
(B220+ IgM
) and immature B cells
(IgM+ B220+) in the bone marrow and of
intermediate and late B cells in the spleen are not significantly
different between wild-type and annexin VI
/
mice (Fig.
4). Similarly, analysis of myeloid,
granulocytic, and monocytic cells in the bone marrow failed to reveal
differences between the control and annexin VI null mutant mice (data
not shown).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Developmental profiles of thymic and splenic T cells.
Thymocytes and splenocytes were prepared in duplicate from wild-type
and annexin VI / mice, triple stained with phycoerythrin-conjugated
anti-CD4, fluorescein isothiocyanate-conjugated anti-CD8, and
BIO-conjugated anti-CD3, and analyzed by FACS. Representative staining
profiles are shown in each case. The average percentages of helper
(CD4+ CD8 ) and cytotoxic (CD4
CD8+) T cells in each population are given in the bar
charts, with error bars showing average differences from the means.
|
|

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 4.
Developmental profiles of bone marrow and splenic B
cells. Bone marrow cells and splenocytes were prepared in duplicate
from wild-type and annexin VI / mice, triple stained with
phycoerythrin-conjugated anti-IgM, fluorescein
isothiocyanate-conjugated anti-IgG, and anti-CD45-B220, and analyzed by
FACS. Representative staining profiles are shown in each case. The
average percentages in each population of those classes of B cells
labeled on the FACS plot are given in the bar charts, with error bars
showing the average differences from the means.
|
|
To investigate possible effects of loss of annexin VI on the heart and
the circulatory system, the resting heart rate and MAP in conscious
mice were measured. This is a relatively new technique that allows
long-term analysis of these parameters over a period of days in
conscious mice. Although the surgical procedure involves the
implantation of a cannula in the femoral artery, the mice regain
consciousness and are able to move freely and behave normally. This
approach also allows the administration of substances known to affect
the circulatory system, such as E. coli endotoxin (LPS),
which induces conditions that mimic septic shock in humans. The average
resting heart rate and MAP in +/+ and
/
mice were recorded over a
12-h period (Fig. 5) and were not
significantly different. Administration of LPS at 12 h led to a
dramatic reduction of MAP with a prolonged recovery phase, 24 h of
which is shown and all of which was also unaffected by loss of annexin
VI.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Blood pressure, heart rate, and endotoxic shock in
annexin VI (AnxVI) knockout mice. MAPs and heart rates were measured in
freely moving conscious mice. Resting heart rates (a) are shown for
wild-type and annexin VI / mice over a 12-h period. Resting MAPs
(b) are also shown over a 12-h period, after which (arrow) 4 mg of
E. coli LPS per kg was administered via the femoral vein,
and the resulting MAP changes were monitored for a further 24 h.
Error bars indicate standard errors of the means.
|
|
 |
DISCUSSION |
The annexin VI gene is thus not a gene essential for mouse
viability. Indeed, there are no obvious effects of loss of annexin VI
on the adult structure and, most probably, on the development of any
tissues. So although annexin VI expression is developmentally regulated
during, among other processes, limb bud formation (17), its
expression is not required to form these structures. At a cellular
level, the predictions of experiments suggesting that annexin VI is
required for budding of clathrin-coated pits (15) or for
caveolar endocytosis (20) are thus also confounded; both such processes are likely to be essential for the viability of cells
and thus the organism. However, annexin VI
/
mice are viable. Our
results do not preclude annexin VI having some minor modulatory role in
vesicle trafficking, and confirmation of normal endocytic and caveolar
endocytosis in annexin VI
/
mice will require analysis at a
cellular level.
While the lack of an overt phenotype could reflect a subtle cellular
role for annexin VI, it is also possible that another member of the
family of 10 known annexins in the mouse could compensate for the
function of annexin VI. However, in the heart, liver, and spleen, none
of annexins I, II, and V are obviously up-regulated (or down-regulated)
at the level of protein expression as determined by Western blotting.
While annexin VI has been shown to be expressed at high levels in the
spleen and lymph nodes, in particular in mature lymphocytes
(3), flow cytometric analysis of the relative myeloid (not
shown) and B- and T-lymphocyte populations revealed no significant
alterations in mice lacking annexin VI. Annexin VI is thus not required
in lymphocyte ontogeny as had been suggested, although it may modulate
lymphocyte function or be involved in immune or proliferative responses.
As with lymphocyte development and function, a broad-range approach
that would allow the detection of a wide range of changes in mice
lacking annexin VI was used to investigate heart and circulatory function. The fact that annexins V and VI are the major cardiac annexins suggests that these proteins have important roles in heart
function (5). Furthermore, experiments suggesting a role for
annexin VI in the regulation of the ryanodine receptor (4, 9) and studies of annexin VI overexpression in the heart
(8) all supported this hypothesis. While the fall in resting
blood pressure for mice lacking inducible nitric oxide synthase was reduced under conditions employed in this study (18),
indicating that genetic manipulation can affect this variable, no such
changes were observed in annexin VI knockout mice. Thus, LPS-induced
circulatory collapse was normal in annexin VI
/
mice, indicating
that the pathways leading to cytokine production and the loss of
vascular tone are normal, while the response of the heart to and its
recovery from the loss of vascular tone were also unaffected.
While these data show that annexin VI is not crucial to heart function,
it is possible, given the familial relationship between annexins V and
VI, that disruption of both genes would reveal a phenotype in the
heart. Alternatively, annexin VI may have a role in the heart under
conditions not yet tested, such as in reperfusion injury or during or
after an infarction. In this context, it is interesting that K201, a
new benzothiazepine derivative which protects against cardiac
reperfusion injury, inhibits the calcium channel activity of annexin V
and binds to the exit pore of the putative ion conductance pathway
(13, 14). The experimental system used in this study will
also be useful in examining the possible effects of caffeine on
cardiovascular function, given that caffeine increases blood pressure
and excites the heart and that it also directly affects the ryanodine
receptor, a possible site of action of annexin VI. Direct analysis of
calcium mobilization and its link to muscle contraction in isolated
cardiomyoctes will also be of interest in order to allow comparison
with the results obtained with the isolated cardiomyoctes of transgenic
mice overexpressing annexin VI (8).
The results presented here provide the first clear information
regarding the role of any annexin in development and organ function.
The fact that loss of annexin VI does not grossly affect any of these
processes raises questions about several proposed roles for annexin VI
in endocytosis, lymphocyte development, and heart function, and it
suggests that annexin VI may have a rather subtle role. However, while
the annexin VI gene is not essential, the generation of annexin VI
/
mice will allow a wide range of further experiments at the
cellular level and should ultimately lead to the generation of mice
lacking multiple annexins.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the Medical Research
Council, the Wellcome Trust, Glaxo-Wellcome, and the European Commission (contract BIO4CT960083).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Physiology, University College London, Gower St., London WC1E 6BT,
United Kingdom. Phone: 0171 380 7744. Fax: 0171 413 8395. E-mail:
s.moss{at}ucl.ac.uk.
 |
REFERENCES |
| 1.
|
Benz, J., and A. Hofmann.
1997.
Annexins: from structure to function.
Biol. Chem. Hoppe-Seyler
378:177-183.
|
| 2.
|
Benz, J.,
A. Bergner,
A. Hofmann,
P. Demange,
P. Göttig,
S. Liemann,
R. Huber, and D. Voges.
1996.
The structure of recombinant human annexin VI in crystals and membrane-bound.
J. Mol. Biol.
260:638-643[Medline].
|
| 3.
|
Clark, D. M.,
S. E. Moss,
N. A. Wright, and M. J. Crumpton.
1991.
Expression of annexin VI (p68, 67 kDa-calelectrin) in normal human tissues: evidence for developmental regulation in B- and T-lymphocytes.
Histochemistry
96:405-412[Medline].
|
| 4.
|
Díaz-Muñoz, M.,
S. L. Hamilton,
M. A. Kaetzel,
P. Hazarika, and J. R. Dedman.
1990.
Modulation of Ca2+ release channel activity from sarcoplasmic reticulum by annexin VI (67-kDa calcimedin).
J. Biol. Chem.
265:15894-15899[Abstract/Free Full Text].
|
| 5.
|
Doubell, A. F.,
C. Lazure,
C. Charbonneau, and G. Thibault.
1993.
Identification and immunolocalisation of annexins V and VI, the major cardiac annexins, in rat heart.
Cardiovasc. Res.
27:1359-1367[Abstract/Free Full Text].
|
| 6.
|
Francia, G.,
S. D. Mitchell,
S. E. Moss,
A. M. Hanby,
J. F. Marshall, and I. R. Hart.
1996.
Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression.
Cancer Res.
56:3855-3858[Abstract/Free Full Text].
|
| 7.
|
Gerke, V., and S. E. Moss.
1997.
Annexins and membrane dynamics.
Biochim. Biophys. Acta
1357:129-154[Medline].
|
| 8.
|
Gunteski-Hamblin, A. M.,
G. J. Song,
R. A. Walsh,
M. Frenzke,
G. P. Boivin,
G. W. Dorn II,
M. A. Kaetzel,
N. D. Horseman, and J. R. Dedman.
1996.
Annexin VI overexpression targeted to heart alters cardiomyocyte function in transgenic mice.
Am. J. Physiol.
270:H1091-H1100[Abstract/Free Full Text].
|
| 8a.
| Hawkins, T. E., and S. E. Moss.
Unpublished data.
|
| 9.
|
Hazarika, P.,
A. Sheldon,
M. A. Kaetzel,
M. Díaz-Muñoz,
S. L. Hamilton, and J. R. Dedman.
1991.
Regulation of the sarcoplasmic reticulum Ca(2+)-release channel requires intact annexin VI.
J. Cell. Biochem.
46:86-93[Medline].
|
| 10.
|
Huber, R.,
J. Romisch, and E. P. Paques.
1990.
The crystal and molecular structure of human annexin V, an anticoagulant protein that binds to calcium and membranes.
EMBO J.
9:3867-3874[Medline].
|
| 11.
|
Jäckle, S.,
U. Beisiegel,
F. Rinninger,
F. Buck,
A. Grigoleit,
A. Block,
I. Gröger,
H. Greten, and E. Windler.
1994.
Annexin VI, a marker protein of hepatocytic endosomes.
J. Biol. Chem.
269:1026-1032[Abstract/Free Full Text].
|
| 12.
|
Kamal, A.,
Y.-S. Ying, and R. G. W. Anderson.
1998.
Annexin VI-mediated loss of spectrin during coated pit budding is coupled to delivery of LDL to lysosomes.
J. Cell Biol.
142:937-947[Abstract/Free Full Text].
|
| 13.
|
Kaneko, N.,
R. Matsuda,
M. Toda, and K. Shimamoto.
1997.
Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative.
Biochim. Biophys. Acta
1330:1-7[Medline].
|
| 14.
|
Kaneko, N.,
H. Ago,
R. Matsuda,
E. Inagaki, and M. Miyano.
1997.
Crystal structure of annexin V with its ligand K-201 as a calcium channel activity inhibitor.
J. Mol. Biol.
274:16-20[Medline].
|
| 15.
|
Lin, H. C.,
T. C. Südhof, and R. G. W. Anderson.
1992.
Annexin VI is required for budding of clathrin-coated pits.
Cell
70:283-291[Medline].
|
| 16.
|
Ortega, D.,
A. Pol,
M. Biermer,
S. Jäckle, and C. Enrich.
1998.
Annexin VI defines an apical endocytic compartment in rat liver hepatocytes.
J. Cell Sci.
111:261-269[Abstract].
|
| 17.
|
Rahman, M. M.,
H. Iida, and Y. Shibata.
1997.
Expression and localization of annexin V and annexin VI during limb bud formation in the rat fetus.
Anat. Embryol.
195:31-39[Medline].
|
| 18.
|
Rees, D. D.,
J. E. Monkhouse,
D. Cambridge, and S. Moncada.
1998.
Nitric oxide and the haemodynamic profile of endotoxin shock in the conscious mouse.
Br. J. Pharmacol.
124:540-546[Medline].
|
| 19.
|
Roes, J., and K. Rajewsky.
1993.
Immunoglobulin D (IgD)-deficient mice reveal an auxiliary receptor function for IgD in antigen-mediated recruitment of B cells.
J. Exp. Med.
177:45-55[Abstract/Free Full Text].
|
| 20.
|
Schnitzer, J. E.,
J. Liu, and P. Oh.
1995.
Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases.
J. Biol. Chem.
270:14399-14404[Abstract/Free Full Text].
|
| 21.
|
Smith, P. D.,
A. Davies,
M. J. Crumpton, and S. E. Moss.
1994.
Structure of the human annexin VI gene.
Proc. Natl. Acad. Sci. USA
91:2713-2717[Abstract/Free Full Text].
|
| 22.
|
Smith, P. D., and S. E. Moss.
1994.
Structural evolution of the annexin supergene family.
Trends Genet.
10:241-246[Medline].
|
| 23.
|
Smythe, E.,
P. D. Smith,
S. M. Jacob,
J. Theobald, and S. E. Moss.
1994.
Endocytosis occurs independently of annexin VI in human A431 cells.
J. Cell Biol.
124:301-306[Abstract/Free Full Text].
|
| 24.
|
Theobald, J.,
P. D. Smith,
S. M. Jacob, and S. E. Moss.
1994.
Expression of annexin VI in A431 carcinoma cells suppresses proliferation: a possible role for annexin VI in cell growth regulation.
Biochim. Biophys. Acta
1223:383-390[Medline].
|
| 25.
|
Theobald, J.,
A. Hanby,
K. Patel, and S. E. Moss.
1995.
Annexin VI has tumour-suppressor activity in human A431 squamous epithelial carcinoma cells.
Br. J. Cancer
71:786-788[Medline].
|
Molecular and Cellular Biology, December 1999, p. 8028-8032, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tomas, A., Futter, C., Moss, S. E.
(2004). Annexin 11 is required for midbody formation and completion of the terminal phase of cytokinesis. JCB
165: 813-822
[Abstract]
[Full Text]
-
Rescher, U., Gerke, V.
(2004). Annexins - unique membrane binding proteins with diverse functions. J. Cell Sci.
117: 2631-2639
[Abstract]
[Full Text]
-
Brachvogel, B., Dikschas, J., Moch, H., Welzel, H., von der Mark, K., Hofmann, C., Poschl, E.
(2003). Annexin A5 Is Not Essential for Skeletal Development. Mol. Cell. Biol.
23: 2907-2913
[Abstract]
[Full Text]
-
Thomas, D. D. H., Kaspar, K. M., Taft, W. B., Weng, N., Rodenkirch, L. A., Groblewski, G. E.
(2002). Identification of Annexin VI as a Ca2+-sensitive CRHSP-28-binding Protein in Pancreatic Acinar Cells. J. Biol. Chem.
277: 35496-35502
[Abstract]
[Full Text]
-
Gerke, V., Moss, S. E.
(2002). Annexins: From Structure to Function. Physiol. Rev.
82: 331-371
[Abstract]
[Full Text]
-
Herr, C., Smyth, N., Ullrich, S., Yun, F., Sasse, P., Hescheler, J., Fleischmann, B., Lasek, K., Brixius, K., Schwinger, R. H. G., Fassler, R., Schroder, R., Noegel, A. A.
(2001). Loss of Annexin A7 Leads to Alterations in Frequency-Induced Shortening of Isolated Murine Cardiomyocytes. Mol. Cell. Biol.
21: 4119-4128
[Abstract]
[Full Text]